Camber is made up of three groups  with one common goal: to be the best generics company in the industry. Camber Pharmaceuticals is rapidly growing and had an industry-leading 28 product approvals in 2022. With the support of our parent company, Hetero, we are poised to have a record number of product approvals and launches in 2023. Hetero, a world leader in API production and vertical manufacturing, is the foundation upon which Camber has maintained a 99% service level for our customers for the past two  years. Hetero is investing over $250 million in the next three years in Camber products. The research and development team consists of over 1,000 scientists working to expand the types of drugs Camber offers, including novel delivery systems and complex molecules.

Biotechnology

Health Care

Life Sciences

Medical Devices

Pharmaceutical

Camber Pharmaceuticals Inc

Kon Ostaficiuk

Pravin Pillai ( Cpa

Dennis Herrera

Veera Kamjula

Shea Flood

Victor Mazzacone

Ron Cerminaro

Kirk Hessels

H. D. Smith

Tom Destefano

Stephen Rutledge

Surya Gandikota

Sales and Marketing

Leadership Team

Data and Analytics Team

Finance and Accounting

Operations and Support

Teams at Camber Pharmaceuticals Inc

Sales and Marketing

Leadership Team

Data and Analytics Team

Finance and Accounting

Operations and Support